View in EDS

Evaluating day +90 donor chimerism as a prognostic marker of clinical outcomes among allogeneic hematopoietic cell transplant recipients who received myeloablative conditioning.

Saved in:
Bibliographic Details
Title: Evaluating day +90 donor chimerism as a prognostic marker of clinical outcomes among allogeneic hematopoietic cell transplant recipients who received myeloablative conditioning.
Authors: Jubas S; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC., Collins K; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC., Obara K; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC., Liu HH; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC., Kemper RM; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC., Kelley ALW; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC., Goel A; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC., Dunlap TC; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; Metrum Research Group, Boston, MA., Zhu J; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC., Randolph RM; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC., Ptachcinski JR; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC; Division of Practice Advancement and Clinical Education, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; UNC Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC., Bizzell ME; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC; UNC Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC., Armistead PM; UNC Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC; Division of Hematology, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., Shaw JR; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC; Division of Practice Advancement and Clinical Education, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; UNC Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC., Snow AE; UNC Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC; Division of Hematology, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., Crona DJ; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC. Electronic address: daniel.crona@unc.edu.
Source: Transplantation and cellular therapy [Transplant Cell Ther] 2026 Jun 18. Date of Electronic Publication: 2026 Jun 18.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42315022
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Evaluating day +90 donor chimerism as a prognostic marker of clinical outcomes among allogeneic hematopoietic cell transplant recipients who received myeloablative conditioning.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jubas+S%22">Jubas S</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Collins+K%22">Collins K</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Obara+K%22">Obara K</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Liu+HH%22">Liu HH</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Kemper+RM%22">Kemper RM</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Kelley+ALW%22">Kelley ALW</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Goel+A%22">Goel A</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Dunlap+TC%22">Dunlap TC</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; Metrum Research Group, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Zhu+J%22">Zhu J</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Randolph+RM%22">Randolph RM</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Ptachcinski+JR%22">Ptachcinski JR</searchLink>; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC; Division of Practice Advancement and Clinical Education, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; UNC Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Bizzell+ME%22">Bizzell ME</searchLink>; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC; UNC Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Armistead+PM%22">Armistead PM</searchLink>; UNC Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC; Division of Hematology, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Shaw+JR%22">Shaw JR</searchLink>; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC; Division of Practice Advancement and Clinical Education, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; UNC Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Snow+AE%22">Snow AE</searchLink>; UNC Transplant and Cellular Therapy Program, University of North Carolina Medical Center, Chapel Hill, NC; Division of Hematology, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.<br /><searchLink fieldCode="AU" term="%22Crona+DJ%22">Crona DJ</searchLink>; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC. Electronic address: daniel.crona@unc.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101774629%22">Transplantation and cellular therapy</searchLink> [Transplant Cell Ther] 2026 Jun 18. <i>Date of Electronic Publication: </i>2026 Jun 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101774629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-6367 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226666367%22">26666367 </searchLink><i>NLM ISO Abbreviation: </i>Transplant Cell Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42315022
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtct.2026.06.024
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Evaluating day +90 donor chimerism as a prognostic marker of clinical outcomes among allogeneic hematopoietic cell transplant recipients who received myeloablative conditioning.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jubas S
      – PersonEntity:
          Name:
            NameFull: Collins K
      – PersonEntity:
          Name:
            NameFull: Obara K
      – PersonEntity:
          Name:
            NameFull: Liu HH
      – PersonEntity:
          Name:
            NameFull: Kemper RM
      – PersonEntity:
          Name:
            NameFull: Kelley ALW
      – PersonEntity:
          Name:
            NameFull: Goel A
      – PersonEntity:
          Name:
            NameFull: Dunlap TC
      – PersonEntity:
          Name:
            NameFull: Zhu J
      – PersonEntity:
          Name:
            NameFull: Randolph RM
      – PersonEntity:
          Name:
            NameFull: Ptachcinski JR
      – PersonEntity:
          Name:
            NameFull: Bizzell ME
      – PersonEntity:
          Name:
            NameFull: Armistead PM
      – PersonEntity:
          Name:
            NameFull: Shaw JR
      – PersonEntity:
          Name:
            NameFull: Snow AE
      – PersonEntity:
          Name:
            NameFull: Crona DJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 06
              Text: 2026 Jun 18
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2666-6367
          Titles:
            – TitleFull: Transplantation and cellular therapy
              Type: main
ResultId 1